Skip to content
Flagship Biosciences
  • About
    • Process
    • Company
    • Our Vision
    • Careers
  • Pharma
    • Image Analysis
    • IHC / IF / ISH Assays
    • Multiplex Assays
    • Data Analysis and Reporting
    • Consultation with Scientific Experts
    • Regulatory Strategy and Support
  • Clinical Diagnostics
    • Clinical Data
    • Approved Partner Program
    • Scientific Advisory Board
  • Technology
  • Resources
    • News
    • Blog
    • Events
    • Posters & Publications
    • Collateral
  • Contact Us

Posters & Publications

Intelligent Pharma Partners: Pathology AI Needs a New Business Model

The true barrier to artificial intelligence (AI) in pathology is not the technology; it’s the business model. Flagship Biosciences believes that the true opportunity for

Read More »
October 18, 2018

2018 Global AI-based Pathology Solutions in Immuno-oncology Technology Innovation Award

Based on its recent analysis of the global market for artificial intelligence (AI)-based pathology solutions in immuno-oncology (I-O), Frost & Sullivan recognizes Flagship Biosciences, Inc.

Read More »
September 18, 2018

Validation of a Muscle-Specific Tissue Image-Analysis Tool for Quantitative Assessment of Dystrophin Staining in Frozen Muscle Biopsies

Key Concepts: Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be as effective as manual

Read More »
September 5, 2018

WHITE PAPER: Using Artificial Intelligence To Determine Patient Response To Immunotherapy

Key Concepts: While the current diagnostic strategies for PD-L1 checkpoint inhibitors identify some responders well, the majority of patients still need diagnostic approaches that better

Read More »
August 13, 2018

POSTER: Methodology for Designing and Validating Computational Pathology Scores for Immune Cell Clustering in Tumor Biopsy Samples

Abstract Background Immune cell clustering is commonly observed in histopathology images. As the frequency and nature of immune cell clustering may represent biological phenomena critical to

Read More »
April 18, 2018

POSTER: Comparison of Multiplexed Imaging Mass Cytometry with Monoplex Immunohistochemistry in FFPE Tissue

Abstract Multiplexed analysis of limited tissue samples can improve our understanding of tumor biology and the tumor microenvironment. Chromogenic and fluorescent multiplexed immunohistochemistry (IHC) approaches

Read More »
April 17, 2018
⟨ Page1 Page2 Page3 Page4 Page5 ⟩

Recent Posts

  • White Paper: Tissue Image Analysis and Biomarker Assessment Implementation Benefits and ROI
  • Biomarkers Strategies and Implementation for Drug Development (Regulatory Webcast Summary)
  • Flagship Spotlight: Caroline Chandler
  • Pharma Tech Outlook Cover Story: Flagship Biosciences – Accelerating Drug Development
  • Flagship Spotlight: Brenna O’Neill

Resources

  • News
  • Blog
  • Events
  • Posters & Publications

READY TO TAKE THE NEXT STEP?

Start Your Consultation Today

Our Services

Pharma

Cell-based image analysis, assays, and partnership to advance clinical trials and regulatory acceptance.

Learn More

Clinical Diagnostics

Dependable clinical diagnostic testing to connect patients to individualized, immuno-oncology therapies.

Learn More

Related Resources

Blog

Posters & Publications

News

Flagship carefully tracks our tissue to ensure we can analyze every assay and stay on schedule.
Sr. Pharmaceutical Research Director
Sr. Pharmaceutical Research Director
We are trying to bridge from the discovery stage to clinical development. Flagship's pathologists and scientists provide critical input and the company helps us organize and analyze an incredible amount of data. I highly recommend Flagship for its expertise and support for drug development projects.
Biopharma Director
Biopharma Director
During clinical trials, I interact with our manufacturing, legal, pre-clinical, and biomarker teams. Our Flagship project manager understands our tight timeline and ensures delivery of the data we need, when we need it.
Biotech Pharmaceutical Operations Director
Biotech Pharmaceutical Operations Director
We are pleased to partner with Flagship Biosciences to integrate their machine learning/AI tools to provide cancer marker detection.
Laboratory Software Solutions Provider COO
Flagship’s image analysis experts are flexible and willing to work with us to develop projects that meet the changing needs of our clinical trials drug development.
Sr. Pharmaceutical Research Director
Flagship has a high reputation as a supplier of advanced IHC services and their CAP-CLIA environment is a perfect complement to our own testing facilities.
Global Oncology Research Database Provider CEO
The ease of leveraging Flagship’s powerful solution is yet another massive differentiator of the company. Clients need not have to change their existing workflows, investments in technology, or even the assays that they use.
CIO Review, Pharma and Life Sciences

About Flagship Biosciences

We are a multi-disciplinary team of pathologists, biologists, analysts, software engineers, and technicians who are committed to creating successful approaches which match patients with life-saving drugs.
Learn More >

Quick Links

  • Pharma
  • Clinical Diagnostics
  • Posters & Publications
  • Events
  • Careers
  • Contact Us
Menu
  • Pharma
  • Clinical Diagnostics
  • Posters & Publications
  • Events
  • Careers
  • Contact Us

Connect With Us

Linkedin
Envelope
7575 West 103rd, Suite 102 Westminster, CO 80021 303.325.5894
  • Copyright 2021 Flagship Biosciences Inc.
  • Sitemap
  • Privacy Policy
  • 7575 West 103rd, Suite 102, Westminster, CO 80021
Search for:
Close Menu

Start Your Consultation Today